Can Bioxytran’s ProLectin-M accelerate viral clearance in mild COVID-19?
Bioxytran reports early antiviral signal for ProLectin-M. Discover what this means for COVID-19 treatment strategy and regulatory risk.
Takeda and Protagonist near FDA decision on novel PV therapy rusfertide
FDA grants Priority Review to rusfertide for polycythemia vera. Discover what this means for treatment standards and market dynamics.
TScan Therapeutics strengthens heme pipeline with dual IND clearances
TScan Therapeutics advances its ALLOHA trial and expands CD45-targeted TCR-T coverage. Discover what this means for relapse prevention.
Ipsen moves closer to EU approval for Ojemda in BRAF-driven childhood brain tumors
Ipsen nears EU approval for Ojemda in BRAF-driven pediatric glioma. Explore regulatory impact, clinical implications, and long-term risks.
Can X4 Pharmaceuticals and Norgine unlock EU access to the first targeted WHIM therapy?
EMA backs mavorixafor for WHIM syndrome. Explore what EU approval could mean for access, evidence standards, and rare immunology treatment.
Scynexis expands SCY-247 program with IV SAD and MAD trial launch
SCYNEXIS advances IV SCY-247 into Phase 1 for invasive candidiasis. Explore what this means for resistance and regulation.
Biomerica’s responder data raises new questions about diet-driven IBS management
Biomerica reports real-world IBS responder data and Medicare coverage. Explore what this means for adoption, reimbursement, and competition.
AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV
AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV. Explore what the Phase 3 data mean for regulation and practice.
Eton Pharmaceuticals expands rare endocrine portfolio with FDA-backed liquid desmopressin
FDA approves DESMODA oral solution for central diabetes insipidus. Explore what this means for dosing precision and rare endocrine care.
What Longeveron Inc.’s Phase 2b results mean for regenerative medicine in aging populations
Longeveron Inc. publishes Phase 2b laromestrocel data in frailty. Explore what it means for stem cell therapy and regulatory next steps.